Q1 Earnings Estimate for HRTX Issued By Northland Capmk

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities research analysts at Northland Capmk issued their Q1 2025 earnings per share estimates for Heron Therapeutics in a report released on Thursday, February 27th. Northland Capmk analyst C. Byrnes anticipates that the biotechnology company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.13) per share. Northland Capmk also issued estimates for Heron Therapeutics' Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS and Q4 2025 earnings at $0.01 EPS.

Several other equities analysts have also issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Friday. StockNews.com raised Heron Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday.

Heron Therapeutics Price Performance

HRTX traded down $0.23 during trading on Monday, hitting $2.24. 3,230,566 shares of the stock traded hands, compared to its average volume of 1,797,269. The business has a 50 day moving average price of $1.69 and a 200 day moving average price of $1.71. Heron Therapeutics has a twelve month low of $1.04 and a twelve month high of $3.93. The company has a market cap of $340.69 million, a price-to-earnings ratio of -12.44 and a beta of 1.60.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Carolinas Wealth Consulting LLC increased its holdings in Heron Therapeutics by 49.4% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 41,356 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 13,669 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of Heron Therapeutics by 1.5% in the fourth quarter. Two Sigma Advisers LP now owns 823,871 shares of the biotechnology company's stock valued at $1,261,000 after buying an additional 12,500 shares during the period. State of Wyoming raised its holdings in Heron Therapeutics by 573.5% in the 4th quarter. State of Wyoming now owns 29,736 shares of the biotechnology company's stock valued at $45,000 after buying an additional 25,321 shares during the last quarter. Stonepine Capital Management LLC bought a new position in Heron Therapeutics in the 4th quarter valued at approximately $1,071,000. Finally, Tang Capital Management LLC boosted its position in Heron Therapeutics by 15.7% during the 4th quarter. Tang Capital Management LLC now owns 2,140,271 shares of the biotechnology company's stock worth $3,275,000 after buying an additional 290,271 shares during the period. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.